Compare ITRI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRI | CRSP |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.1B |
| IPO Year | 1993 | 2016 |
| Metric | ITRI | CRSP |
|---|---|---|
| Price | $97.77 | $55.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $135.78 | $71.50 |
| AVG Volume (30 Days) | 476.3K | ★ 1.8M |
| Earning Date | 02-17-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.43 | N/A |
| EPS | ★ 5.57 | N/A |
| Revenue | ★ $2,408,401,000.00 | $38,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | $1,376.73 |
| P/E Ratio | $17.53 | ★ N/A |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $90.11 | $30.04 |
| 52 Week High | $142.00 | $78.48 |
| Indicator | ITRI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 49.99 |
| Support Level | $96.31 | $51.00 |
| Resistance Level | $101.21 | $60.90 |
| Average True Range (ATR) | 2.58 | 3.28 |
| MACD | 0.34 | 0.23 |
| Stochastic Oscillator | 48.91 | 46.97 |
Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.